| Drug Name |
Anagrelide |
| Drug ID |
BADD_D00139 |
| Description |
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274] |
| Indications and Usage |
For the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01XX35 |
| DrugBank ID |
DB00261
|
| KEGG ID |
D07455
|
| MeSH ID |
C021139
|
| PubChem ID |
135409400
|
| TTD Drug ID |
D0D1HW
|
| NDC Product Code |
13668-453; 13668-462 |
| Synonyms |
anagrelide | Agrylin | BL 4162A | Agrelin | anagrelide hydrochloride | imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride | 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochloride |
